Powered by

Arcturus Therapeutics Announces Second Quarter Financial Results and Provides a Corporate Update

Aug 15, 2019 - GlobeNewswire
Financial Results

Ultragenyx Pharmaceutical, Inc. expands collaboration, becoming Arcturus' largest shareholderCystic Fibrosis Foundation increases commitment to $15 millionArcturus receives Orphan Drug Designation from the U.S. FDA for ARCT-810Conference call and audio webcast at 4:30 PM ET today

SAN DIEGO, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. ("Arcturus Therapeutics") (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and comm...